BillTrack50 logo
Free Signup Login
Bill

Bill > S517

NJ S517

NJ S517
Provides that sterile syringe access programs are inherently beneficial uses.

summary

Introduced
01/14/2020
In Committee
01/14/2020
Crossed Over
Passed
Dead
01/11/2022

Introduced Session

2020-2021 Regular Session

Bill Summary

This bill would revise the definition of "inherently beneficial use in the "Municipal Land Use Law," P.L.1975, c.291 (C.40:55D-1 et seq.) (MLUL) to include a sterile syringe access program. Under the MLUL, if a use is deemed inherently beneficial it presumptively satisfies the positive criteria for the grant of a use variance under subsection d. of section 57 of P.L.1975, c.291 (C.40:55-70). Sterile syringe access programs are designed to prevent the spread of HIV, hepatitis C, and other blood borne pathogens, and have been proven effective in reducing the spread of these pathogens without adverse social impacts or an increase in drug abuse. Additionally, the programs provide drug users with a bridge to treatment and other social services. This bill would make it easier for the programs to be established, providing more individuals with access to the program benefits.

AI Summary

This bill would revise the definition of "inherently beneficial use" in the Municipal Land Use Law to include a sterile syringe access program. These programs are designed to prevent the spread of infectious diseases like HIV and hepatitis C by providing clean needles and other supplies to drug users. They also connect users to treatment and social services. By designating these programs as inherently beneficial, the bill would make it easier for them to be established, allowing more individuals to access their benefits.

Committee Categories

Health and Social Services

Sponsors (2)

Last Action

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee (on 01/14/2020)
(3 Companion Bills)

bill text

bill summary

Loading...

bill summary

Loading...
Loading...